Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 8:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 620 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
Interventions
Canagliflozin (JNJ-28431754), Sitagliptin, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo

NCT05949008
Conditions
NIDDM, Obesity
Interventions
Metformin Extended Release (ER) Oral Tablet, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Healthy Volunteers
Interventions
Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/500 mg, CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Fresno, California • Fort Lauderdale, Florida • Gurnee, Illinois + 4 more
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
BMS-820132, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida
Conditions
Diabetes, Pregnancy
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Jackson, Mississippi + 7 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin, Sulphonylurea
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
85
States / cities
Mobile, Alabama • Goodyear, Arizona • Mesa, Arizona + 82 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
72
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 67 more
Conditions
Diabetes Mellitus, Type 2, Metformin Adverse Reaction
Interventions
Metformin, Placebo
Drug
Lead sponsor
St. Louis University
Other
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 110 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Glargine Insulin
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetes Mellitus Type 2
Interventions
insulin glargine, metformin, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
74
States / cities
Phoenix, Arizona • Searcy, Arkansas • Concord, California + 63 more
Conditions
Healthy, Type 2 Diabetes Mellitus
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 2 Interventional Results available

A Study of LY2189102 in Patients With Type 2 Diabetes

NCT00942188
Conditions
Type 2 Diabetes
Interventions
LY2189102, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Mobile, Alabama • Anaheim, California • Chula Vista, California + 15 more
Conditions
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
Interventions
exenatide, Other antidiabetic therapies, No diabetes therapy
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
363,766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Waltham, Massachusetts
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Type 2 Diabetes Mellitus
Interventions
LCQ908A, Placebo, Sitagliptin, metformin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
48
States / cities
Mesa, Arizona • Little Rock, Arkansas • Buena Park, California + 39 more
Conditions
Type 2 Diabetes
Interventions
Muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
70
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mesa, Arizona + 67 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

NCT02911792
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Metformin, Glipizide 5 MG
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Conditions
Diabetes Mellitus Type 2
Interventions
ORMD-0801 Dose # 1, ORMD-0801 Dose # 2, Placebo
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
20 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Tustin, California
Conditions
Type 2 Diabetes
Interventions
Mesenchymal Precursor Cells (MPCs)
Drug
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Garden Grove, California • Miami, Florida • Orlando, Florida + 15 more
Completed Phase 3 Interventional Results available

Dapagliflozin DPPIV Inhibitor add-on Study

NCT00984867
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
45
States / cities
Huntsville, Alabama • Ozark, Alabama • Anaheim, California + 42 more